Evidence map›Paper›PMID 40452163›Full record

ArticleInfluenza and other respiratory viruses2025

Evaluating the Impact of Different Methods on the Timing and Duration of RSV Epidemics: Analysis of Surveillance Data From the GERi (Global Epidemiology of RSV in Hospitalized and Community Care) Study.

Lisa Staadegaard, Marco Del Riccio, Susanne Heemskerk, Michel Dückers, Rodrigo A Fasce, Patricia Bustos, Q Sue Huang, Cheryl Cohen, Jocelyn Moyes, Vernon Jian Ming Lee and 9 more

Abstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lisa StaadegaardNetherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.ORCID 0000-0002-6985-3541
Marco Del RiccioNetherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.
Susanne HeemskerkNetherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.ORCID 0009-0007-7267-0897
Michel DückersNetherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.ORCID 0000-0001-7746-053X
Rodrigo A FasceSubdepartment of Viral Diseases, Public Health Institute of Chile, Santiago, Chile.
Patricia BustosRespiratory and Exanthematic Virus Section, Public Health Institute of Chile, Santiago, Chile.
Q Sue HuangInstitute of Environmental Science and Research, Wellington, New Zealand.ORCID 0000-0002-3923-5195
Cheryl CohenCentre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.ORCID 0000-0003-0376-2302
Jocelyn MoyesCentre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.
Vernon Jian Ming LeeMinistry of Health, Singapore, Singapore.
Li Wei AngMinistry of Health, Singapore, Singapore.ORCID 0000-0002-0036-255X
Susana MongeNational Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Isabel Martínez-PinoPublic Health Directorate, Castilla y León Regional Ministry of Health, Valladolid, Spain.
Mathieu BangertHealth Economics & Value Assessment Vaccines, Sanofi Vaccines, Lyon, France.
Rolf KramerHealth Economics & Value Assessment Vaccines, Sanofi Vaccines, Lyon, France.
John PagetNetherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.ORCID 0000-0002-1503-2481
Foekje F StelmaNetherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.
Jojanneke van SummerenNetherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.
Saverio CainiNetherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.ORCID 0000-0002-2262-1102

Funding

AstraZenecaSanofi
6 · The paper itself

Abstract

backgroundWe previously reviewed methods for estimating the timing of respiratory syncytial virus (RSV) epidemics. This study examines the impact of various estimation methods on determining the start, end, duration, and capture rate of RSV epidemics.

methodsWe applied eight estimation methods to RSV surveillance data from the Global Epidemiology of RSV (GERi) study, covering Chile, New Zealand, Singapore, South Africa, Spain, and the United States: 3% and 10% positivity rate, moving epidemic method (MEM), mean positivity, 1.2% total detections, mean and 60% mean number, and 75% average annual percentage (AAP). We compared the median start, end, duration, and capture rate of RSV epidemics obtained from these methods.

resultsWithin countries, the median duration of RSV epidemics varied by over 10 weeks, and the median capture rates ranged from > 95 to < 60%, depending on the estimation method. Generally, the 3% positivity rate method identified the longest RSV epidemics (earliest median start and latest end, and highest capture rate). The 10% positivity rate, MEM, and 75% AAP methods indicated the shortest RSV epidemics with the lowest capture rate. The remaining four methods produced intermediate results.

conclusionsThese findings underscore the importance of selecting estimation methods suited to the surveillance system and the intended use, whether for outbreak alert, planning, or targeted interventions.

Indexed as

EpidemicsEpidemiological MonitoringRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsGlobal HealthHospitalizationHumansInfantNew ZealandSingaporeTime FactorsUnited Statesepidemicestimation methodrespiratory syncytial virus

Identifiers

PMID40452163
PMCPMC12127213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.